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Objective: Based on patient records and expertise of clinical specialists, this study used questionnaires to evaluate physicians’
views on clinical characteristics of sIBM that may impact on premature mortality and CoDs in these patients.
Methods: Thirteen physicians from seven countries completed two questionnaires online between December 20, 2012 and
January 15, 2013. Responses to the first questionnaire were collated and presented in the second questionnaire to seek
elaboration and identify consensus.
Results: All 13 physicians completed both questionnaires, providing responses based on 585 living and 149 deceased patients
under their care. Patients were reported to have experienced dysphagia (60.2%) and injurious falls (44.3%) during their disease.
Over half of physicians reported that a subset of their patients with sIBM had a shortened lifespan (8/13), and agreed that
bulbar dysfunction/dysphagia/oropharyngeal involvement (12/13), early-onset disease (8/13), severe symptoms (8/13), and
falls (7/13) impacted lifespan. Factors related to sIBM were reported as CoDs in 40% of deceased patients. Oropharyngeal
muscle dysfunction was ranked as the leading feature of sIBM that could contribute to death. The risk of premature mortality
was higher than the age-matched comparison population.
Conclusions: In the absence of data from traditional sources, this study suggests that features of sIBM may contribute to
premature mortality and may be used to inform future studies.
Keywords: Myositis, inclusion body, cause of death, mortality, deglutition disorder, neuromuscular disease, myositis,
morbidity
INTRODUCTION
Sporadic inclusion body myositis (sIBM), also
called, inclusion body myositis (IBM), is a progres-
sive, degenerative inflammatory myopathy charac-
terized by slowly progressive weakness and atrophy
of muscles of the limbs, face and pharynx [1]. This
chronic, debilitating condition affects more men than
women (3:1 ratio) [2, 3], and in most cases the onset of
symptoms occurs after the age of 50 years [3–5]. In the
USA and Europe, sIBM is categorized as an orphan
condition; nevertheless, sIBM is the most common
myopathy in thoseagedover50years [6–8].Theexist-
ing literature reports a general population prevalence
of 1.1 per million in Turkey [9], 4.9 per million in the
Netherlands [10], 9.8 per million in Japan [11], 10.7
per million in the USA [4], 14.9 per million in West-
ern Australia [12], 33 per million in Norway [13] and
50.5 per million in South Australia [14]. It is possi-
ble, however, that these figures are underestimates,
due to incomplete case ascertainment, misdiagnosis
and delayed diagnosis of sIBM [15]. Consistent with
this possibility, prevalence estimates have increased
over time in follow-up studies [12, 14, 16], which may
reflect improved disease awareness and diagnoses.
Based on the available literature, the most common
presenting symptoms of sIBM, reported in over 35%
of patients, are falls and difficulty standing [1, 12,
15]. In a small proportion of patients, the presenta-
tion includes difficulties in performing certain tasks
(e.g. gripping, climbing stairs) [1, 15, 17]. As the
disease progresses, patients continue to lose muscle
strength at a rate of 3.5–16.8% per year [4, 18–20];
several years after disease onset, most patients require
assistance with daily activities, as well as need-
ing ambulatory aids such as a cane, walker or
wheelchair [1, 4, 19, 21]. Weakening or dysfunction
of the pharyngeal and esophageal muscles can lead
to dysphagia (difficulty with swallowing), which is
experienced by 40–80% of patients during the course
of sIBM, and can result in choking, weight loss, aspi-
ration and pneumonia [1, 5, 19, 20, 22–25]. Currently,
there is no approved effective pharmacological treat-
ment for sIBM; physiotherapy, prescribed by most
physicians who care for these patients, has been
shown to be of some help [26], and some receive local
treatment for severe dysphagia [27], as well as general
supportive care to manage their symptoms [20].
Few published studies have reported on the natural
history of sIBM [4, 18–20, 28–30] or on mortal-
ity and causes of death (CoD) associated with the
disease [19, 20]. In both of the studies investigat-
ing mortality in patients with sIBM, no significant
impact on lifespan compared with the general pop-
ulation was reported [19, 20]. Furthermore, in a
Dutch study comparing patients with sIBM with the
age-matched general population, diseases of the res-
piratory system (41.3% of patients with sIBM versus
11.5% of the general population), and specifically
pneumonia (28.3% versus 4.4%), as well as cachexia
(severe wasting with loss of weight and muscle mass,
6.5% versus 0.1%), were identified as leading CoDs
in individuals in the 80–85 years age category [19].
While these studies provide insights into the clinical
course of sIBM, the conclusions that can be drawn are
limited by their small sample sizes and short follow-
up times. The paucity of data on the potential impact
of sIBM on premature mortality may reflect the chal-
lenges of obtaining data on sIBM and other rare
diseases from traditional data sources. We therefore
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conducted a survey to evaluate the views of physi-
cians who are treating or have treated patients with
sIBM (based on their clinical experience and patient
records) in order to assess the contribution of this
condition to premature mortality. To the best of our
knowledge, this is the largest evaluation of patients
with sIBM using this methodology.
MATERIALS AND METHODS
This study used questionnaires to assess the views
of physicians on the risk of premature mortality and
CoDs in patients with sIBM, based on their clinical
experience and patient records. The study was car-
ried out using a method similar to the Delphi panel
technique, which uses iterative rounds of question-
naires to gather relevant data, along with the opinions
of experts which are subsequently presented to the
respondents to seek consensus [31]. On December
18, 2012, this study was declared exempt from review
by the Research Triangle International Committee for
the Protection of Human Subjects, owing to the fact
that no information that would allow the identifica-
tion of any patient was ever provided to the study
team or the study sponsor by the respondents.
A group of physicians were initially contacted to
request their participation in the present survey study.
Of those invited, 13 expert physicians (neurologist
and/or neuromuscular specialist, n = 10; rheuma-
tologist, n = 2; systemic disease specialist, n = 1)
from seven countries (Australia, France, Germany,
Netherlands, Sweden, UK and USA) who had at
least 5 years of experience and were actively treat-
ing patients with sIBM responded. The participating
physicians were sent a preliminary questionnaire that
they did not need to respond to but that invited them to
evaluate the medical records of their patients, whom
they had diagnosed with sIBM. This was followed
by a two-stage questionnaire, for which physicians
could use the information that they had gathered dur-
ing the preliminary questionnaire and did not need
to refer to their patient medical records, other than
to confirm numbers, where applicable (Supplement,
Tables 1–3). The questions were designed to cap-
ture summary-level patient data from physicians and
their views on premature mortality and CoDs among
patients with sIBM, based on their overall clini-
cal experience. The questionnaires were completed
online, with physicians able to respond anonymously,
at their convenience, within a specified period
(December 20–30, 2012 for round 1; January 7–15,
2013 for round 2). The first questionnaire consisted
of 20 questions (Supplement, Table 2) and the second
questionnaire consisted of 17 questions (Supplement,
Table 3). Between rounds 1 and 2 of the process,
physician responses were anonymized before being
analyzed, collated and summarized; no formal cod-
ing or thematic analyses were undertaken. In order
to seek consensus, selected collated responses from
round 1, which reflected the views of at least half
of the participating physicians, were then presented
in round 2. This semi-iterative process was to deter-
mine whether the physicians would elaborate on their
responses based on information their colleagues had
provided. Unique or rare responses from round 1 were
not presented in round 2 of the questionnaire.
Responses to the questionnaires were collected
as counts or free-text answers. Quantitative data
were assessed to calculate means, frequencies and/or
standard deviations; for ranking questions, mean
scores were calculated and used to rank the relevant
features. Qualitative data were assessed by two
analysts who independently summarized responses
from all participating physicians; the data were
compared and any minor discrepancies in qualitative
summaries were resolved in order to harmonize the
results. The standardized mortality ratio (SMR) with
95% confidence intervals (CIs) was calculated as the
number of deceased patients with sIBM from this
dataset divided by the number of deaths that would be
expected if the population had the same age-specific
mortality as the external comparison population (US
general population, based on the 2010 census).
RESULTS
Patient cohorts
All 13 physicians completed the questionnaires.
Between rounds 1 and 2 of the questionnaire, physi-
cians may have elaborated on their responses, but
no physicians changed their response. The responses
received were based on 734 patients who had been
under the care of the physicians (Table 1). Over one-
third of patients were from the USA (n = 298, 40.6%)
and over one-quarter were from France (n = 198,
27.0%).
At the time of completing the questionnaire,
585 patients were living and 149 were deceased.
Table 2 summarizes the age ranges of living and
deceased patients with sIBM who were under the care
of the 13 physicians. The majority of living patients
were aged 61–80 years (61–70 years, 34.5%; 71–80
years, 34.9%) and the majority of deceased patients
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Table 1
Number of patients under the care of the physicians in each country
Country Total number of Number of living Number of deceased
patients, n (%) patients, n (%) patients, n (%)
(N = 734) (n = 585) (n = 149)
Australia (3 physicians) 94 (12.8) 79 (13.5) 15 (10.1)
France (1 physician) 198 (27.0) 187 (32.0) 11 (7.4)
Germany (1 physician) 35 (4.8) 35 (6.0) 0 (0.0)
Netherlands (1 physician) 19 (2.6) 12 (2.1) 7 (4.7)
Sweden (1 physician) 21 (2.9) 18 (3.1) 3 (2.0)
UK (1 physician) 69 (9.4) 45 (7.7) 24 (16.1)
USA (5 physicians) 298 (40.6) 209 (35.7) 89 (59.7)
were over 61 years of age (61–70 years, 22.8%;
71–80 years, 36.9%; >80 years, 24.8%).
Typical clinical characteristics of patients with
sIBM
The typical clinical characteristics of patients with
sIBM, based on the experience of the physicians,
are summarized in Table 3. The physicians estimated
that a lower percentage of their patients had “fast-
progressing sIBM” (12.7%; defined as clinically
significant deterioration in limb, bulbar or diaphrag-
matic strength over 4 months or less) than “slow-
progressing sIBM” (77.3%). The mean reported time
from diagnosis to using a cane was 3.9 years; the cor-
responding time to using a wheelchair was 10.5 years.
However, additional information gathered from the
free text responses indicated that several physicians
found this question difficult to answer owing to
the variability in disability levels at the point of
sIBM diagnosis, which may be years after the onset
of symptoms. Physicians reported that, on average,
patients experienced symptoms for 4.5 years before
a formal diagnosis was made. Of the patients who
had progressed to the point of needing a full-time
caregiver, physicians reported that the majority were
using an unpaid caregiver (75.0%) rather than a pro-
fessional caregiver or service (29.0%).
More than half of the patients were reported to
have experienced dysphagia (60.2%), a proportion of
whom developed aspiration pneumonia (22.7%). Just
fewer than half of the patients were reported to have
experienced an injurious fall (44.3%). Physicians
reported that the most common injury experienced by
these patients was bruising (stated by 12/13 physi-
cians), followed by broken arm or leg (10/13) and
broken hip (9/13).
Features of sIBM that can impact on lifespan
Physicians were asked to comment on the impact
of specific features of sIBM on lifespan. Twelve
Table 2
Age ranges of living and deceased patients under the care of 13
physicians from seven countries
Age range Number of living Number of deceased
patients patients
(N = 585) (N = 149)
<40 years 2 0
41–50 years 19 4
51–60 years 80 19
61–70 years 202 34
71–80 years 204 55
>80 years 78 37
of the 13 physicians agreed that patients with bul-
bar dysfunction (abnormal swallowing and speech),
dysphagia and oropharyngeal involvement had a
shortened lifespan. Over half of the physicians also
agreed that patients with early-onset sIBM (8/13) and
younger patients with more severe symptoms (8/13)
had a shortened lifespan, particularly among those
patients who developed severe dysphagia and weak-
ness leading to immobility. Approximately half of
physicians agreed that falls may potentially shorten
lifespan (7/13); additional information gathered from
free text responses indicated that this was owing
to the fact that falls compromised mobility, led to
head injuries or had secondary consequences (e.g.
sepsis), and were recognized as being more likely
to lead to complications in older patients than in
younger patients. Ten of the 13 physicians reported
that patients with sIBM had a shortened lifespan
compared with the general population, a majority of
whom (8/10) thought this was only in a subset of
patients, primarily those experiencing severe dyspha-
gia.
Clinical characteristics and CoDs among
deceased patients with sIBM
Among deceased patients who were under the care
of physicians (n = 149), the mean age at diagnosis
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Table 3
Typical clinical characteristics of patients with sIBM based on the
experience of 13 physicians from seven countries
Characteristics
Type of sIBM, mean proportion of patients, % (range)
“Fast progressing”a 12.7 (0–30)b
“Slow progressing” 77.3 (20–100)





Patients using a caregiverc, mean proportion of patients, %
Professional caregiver/service 29.0
Unpaid caregiverd 75.0
Clinical characteristics of sIBM that patients have experienced
over the course of illness, mean proportion of patients, % (range)
Dysphagia 60.2 (25–90)
Injurious fallse 44.3 (10–100)
Injuries typically sustained by the patients who have experienced
an injurious fall, number of physicians selecting





aDefined as clinically significant deterioration in limb, bulbar or
diaphragmatic strength over 4 months or less. bThe range reported
in the table for proportion of patients with “fast progressing”
sIBM is based on the following responses: 0% of patients, 2
physicians; 5% of patients, 3 physicians; 10% of patients, 2 physi-
cians; 20% of patients, 5 physicians; 30% of patients, 1 physician.
cExpressed as the proportion of patients who have progressed to
the point of needing a full-time caregiver. dUnpaid caregiver can
include, but is not limited to, a spouse, child or family member.
eFalls requiring medical attention. sIBM, sporadic inclusion body
myositis.
was reported to be 62.7 years (range: 60–82 years),
and patients had experienced symptoms for a mean
of 4.5 years (4–5 years) before diagnosis of sIBM.
The mean time between diagnosis and death was
11.2 years (6–20 years).
All CoDs in patients with sIBM (regardless of
relationship with sIBM) were reported by physicians
based on their clinical experience (Table 4). When
physicians were asked to subdivide CoDs according
to age group, aspiration and pneumonia were reported
to have occurred in all age categories except the
41–50 and 51–60 years age categories (Supplement,
Table 4). For approximately 40% of the deceased
patients (n = 57), factors related to sIBM were con-
sidered to be either a primary CoD (death occurred
owing to an event directly related to sIBM, n = 26)
or a secondary CoD (death did not occur directly
owing to sIBM but would probably not have occurred
Table 4
All causes of death in patients with sIBM based on the experience
of 13 physicians from seven countries
Cause of death
Respiratory complications (excluding aspiration pneumonia)
Complications arising from dysphagia (including aspiration
pneumonia)
Complications arising from falls
Cardiovascular causes (MIa, chronic heart failure, stroke)
Cancers/malignancy (transitional cell carcinoma, colon cancer,
male breast cancer, leukemia, acute lymphoblastic leukemia,
prostate cancer, lung cancer)










aThis abbreviation was not defined by the respondent. bReported
by a practitioner in the Netherlands for one patient. Euthanasia
is legal in the Netherlands, but only for patients experiencing
unbearable suffering and when strict procedures are adhered to
[19].
if the patient had not have had sIBM, e.g. dyspha-
gia giving rise to aspiration and pneumonia, n = 31).
However, in approximately 40% of deceased patients
(n = 54), the CoD was not thought to be associated
with factors related to sIBM. Physicians ranked fea-
tures of sIBM that could have contributed to the
death of the deceased patients who were under their
care (Fig. 1) and reported the most common factor
to be oropharyngeal muscle dysfunction. The most
commonly reported end-of-life setting for deceased
patients with sIBM was the home or a nursing home,
whereas the least common setting was a rehabilitation
center (Fig. 2).
Risk of premature mortality in patients with sIBM
Based on this dataset, patients with sIBM who
were aged 41 years and older had an approximately
7-fold higher risk of premature mortality than the
age-matched external comparison population (SMR,
6.58; 95% CI, 5.6–7.7). As expected, the risk of pre-
mature mortality in patients with sIBM decreased
with increasing age, but was still approximately
5-fold higher than the age-matched external compari-
son population in patients over 70 years of age (SMR,
4.82; 95% CI, 3.9–5.9).
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Fig. 1. Ranked features of sIBM that can contribute to death, based on the experience of 13 physicians from seven countries. Features
presented for ranking were based on the physicians’ responses in round 1 of the questionnaire. Each physician was asked to score the features
of sIBM shown above on the basis of contribution to death in the patients they were following (1 = most common, 5 = least common). Five
physicians did not think features of sIBM contributed to death. Of those physicians who provided scores, mean scores were calculated and
used to rank features. Physicians did not expand on which comorbidities associated with sIBM could contribute to death. sIBM, sporadic
inclusion body myositis.
Fig. 2. Ranked end-of-life settings for patients with sIBM, based on the experience of 13 physicians from seven countries. Each physician
was asked to score the end-of-life settings shown above (1 = most common, 5 = least common). Based on all the physicians’ responses, the
mean score was calculated and used to rank the settings. sIBM, sporadic inclusion body myositis.
DISCUSSION
This study, which used questionnaires, was
designed to capture the clinical experience of
13 physicians based on their patient records and direct
clinical contact with patients with sIBM (734 patients
with sIBM in total). The questionnaires assessed clin-
ical characteristics of sIBM that could contribute to
premature mortality and CoDs in patients with sIBM,
based on the responses of physicians in Australia,
Europe and the USA. This analysis revealed that
physicians are of the view that a large proportion of
their patients experience comorbidities that could be
attributed to sIBM and that features of sIBM may
impact on the risk of premature mortality in 40% of
their patients (n = 57).
The physicians in this study were asked to describe
the typical clinical characteristics of their patients.
Consistent with the description of sIBM as a slowly
progressive weakness and atrophy of muscles, the
majority of patients were categorized as having
“slow-progressing sIBM” [1]. In this study, the time
to using a cane or wheelchair was reported to be 3.9
and 10.5 years, respectively, which is shorter than that
reported in other studies (walking stick, 11 years;
wheelchair, 13–16 years) [5, 19, 20]. This differ-
ence may be explained by the fact that the present
study assessed time since diagnosis of sIBM, while
other studies assessed time since symptom onset;
it is well known that there can be a long period
between the onset of symptoms and the diagnosis
of sIBM (4.5 years in this study) [20, 22]. If we
account for the average time that patients experi-
enced symptoms before formal diagnosis, the time
to using an ambulatory aid is similar between the
present study and previously reported observations.
The physicians reported that 60% of their patients
had experienced dysphagia in the course of their ill-
ness, which is within the range reported by several
other studies (20–80%) [1, 5, 10, 19, 22–24, 32].
Nearly half of the patients (44%) were also reported
to have experienced injurious falls, which is lower
than the proportion of patients reporting frequent falls
in a study by Badrising et al. (73%) [5]. However,
this may reflect differences in the patient populations
or in the definition used to assess falls (the propor-
tion of patients experiencing injurious falls versus
the proportion of patients experiencing periods of
frequent falls). Overall, the prevalence of clinical
characteristics of sIBM reported for the population
described in this study (e.g. dysphagia, falls) were
generally within the range reported in other studies,
supporting the present questionnaire-based method-
ology to assess CoDs and risk of premature mortality
in patients with sIBM, for which there is a paucity of
data.
The majority of the physicians in the present study
reported that a subset of patients with sIBM had a
shortened lifespan. Nearly all the physicians agreed
that patients with bulbar dysfunction, dysphagia or
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oropharyngeal involvement, which are features of
sIBM, impacted on lifespan. Furthermore, over half
of the physicians agreed that younger patients experi-
encing severe symptoms and those with early disease
onset had a shortened lifespan, particularly among
patients who developed dysphagia or who had weak-
ness leading to immobility. Over half of physicians
also agreed that patients experiencing falls had a
shortened lifespan, particularly older patients and
cases where falls led to head injuries, secondary
complications (e.g. sepsis) or immobility. Given that
40–60% of patients experience dysphagia (a pro-
portion of whom experience severe dysphagia) or
injurious falls, the present study suggests that life-
span may be affected in a large proportion of patients.
In a recent study of Dutch patients with sIBM who
died, lifespan was not reported to be shortened versus
the Dutch general populations [19]. A similar find-
ing was reported in a study of French and British
patients (using the French general population as the
reference population) [20]. The discrepancy between
the current study and the Dutch and French/British
studies may be due to differences in study design,
patient populations, or the small sample sizes being
investigated (n = 25–46). Furthermore, Cox et al. and
Benveniste et al. assessed lifespan in the entire sIBM
population in their studies, and did not consider
subsets of patients (e.g. those with severe symp-
toms) in whom lifespan may have been affected
by sIBM.
While sIBM is rarely considered a direct CoD, it
is recognized that some deaths may be related to
complications of the disease (e.g. pneumonia aris-
ing from dysphagia) [19, 20]. Indeed, in the present
study, physicians considered factors related to sIBM
to have contributed to the death of almost half of the
deceased patients under their care, and the risk of pre-
mature mortality was 5–7-fold higher in patients with
sIBM than in the age-matched comparison popula-
tion. The highest-ranked feature of sIBM considered
to contribute to death was oropharyngeal muscle
dysfunction, which can lead to dysphagia and sub-
sequently aspiration and pneumonia [19, 20, 22].
Consistent with this, aspiration and pneumonia were
reported as CoDs in the 61–70 years, 71–80 years
and >80 years age categories, which contained almost
85% of the patients under the care of the physicians.
Results on CoD in the present study are consistent
with those of Cox et al., who reported that diseases
of the respiratory system, including pneumonia and
cachexia, all of which can arise from dysphagia,
were leading CoDs in the sIBM cohort versus the
general population in the 80–85 years age category
[19]. While these studies highlight leading CoDs in
patients with sIBM, further studies are needed to
more fully investigate CoDs in these patients, includ-
ing estimates of their relative frequency.
To date, there is a paucity of information on
mortality and CoD in patients with sIBM. This prob-
ably reflects the difficulty of capturing these data in
patients with this rare disease. Until 2010, sIBM did
not have an International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM)
code; therefore, traditional data sources (e.g. medical
records) would have reported only conditions related
to sIBM, rather than sIBM itself (as a diagnosis or
CoD). Furthermore, owing to the protracted nature
of sIBM, patients are likely to be treated by several
different physicians, so retrospective studies of med-
ical records would not necessarily provide a patient’s
complete medical history. To overcome these issues,
this study used questionnaires to assess the views of
physicians based on their broad clinical experience
and is, to the best of our knowledge, the largest assess-
ment of patients with sIBM using this approach. The
methodology ensured that all physicians had an equal
voice to express their views and, using two iterations
of enquiry, provided the opportunity to seek elabora-
tion or identify consensus. The findings of this study
provide important insights into the real-world views
of physicians with different specialties in different
countries on the burden of sIBM, and can be used
to support and contextualize studies performed using
traditional data sources. Future studies are needed
to comprehensively assess potential risks of sIBM
and further investigate complications that could arise
from features of the disease, such as sleep disordered
breathing as a result of oropharyngeal muscle dys-
function [33, 34] or injuries arising from falls.
There are a number of limitations of this study that
may have introduced bias, such as the fact that the
findings were based on information from 13 physi-
cians from only seven countries, with variable clinical
experience of sIBM. While the physicians were
requested to assess patient clinical records before
completing the questionnaires, physicians were not
required to cross-check their responses against their
clinical charts. The information reported may there-
fore have been influenced by impressions from their
experience and recall bias, with a potential to have
overestimated the frequency of severely affected
patients. For those physicians following only a few
patients with sIBM, or with limited number of years
in practice, experience may not completely reflect
74 M.A. Price et al. / Causes of Death in Patients with sIBM
the actual real-world situation. Furthermore, owing
to the nature of data collection, some information
may not have been captured. For example, severely
affected patients with sIBM are more likely than those
with mild or moderately affected disease to be lost at
follow-up at tertiary centers owing to the difficulty of
transporting them. However, to overcome these limi-
tations, the methodology assessed the average views
of the physicians and sought consensus among them,
where appropriate, in part to gain a better under-
standing of the consistency of views between the
physicians. Another limitation is that patients within
a country may have moved between the recruited
physicians over the course of their disease, and there
is therefore a small but existing possibility that data
for some patients may have been duplicated. How-
ever, this does not reduce the significance or impact
of the findings, which were based on summary-level
patient data and the general views of the physicians.
Finally, the SMR data should be interpreted with cau-
tion owing to the large variation in patient mortality
recorded by the participating physicians.
CONCLUSION
This study provides important insights into the
clinical characteristics and CoDs in patients with
sIBM. It suggests an increased risk of mortality in
these patients relative to an age-matched compari-
son population, particularly in those with impaired
swallowing and subsequent aspiration and pneumo-
nia. The findings complement and contextualize what
is already known in the field, as well as providing
novel insights into the features of sIBM that physi-
cians view as contributing to premature mortality.
The lack of unanimity among physicians in their
responses to some questions highlights the need for
further prospective studies, preferably those that are
population-based and have longitudinal follow-up, to
confirm the findings of the present study. Neverthe-
less, these results highlight that there is a recognized
need to manage the consequences of sIBM, primar-
ily severe dysphagia, in order to reduce their potential
contribution to premature mortality.
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